Introduction
Idiopathic myelofibrosis, or agnogenic myeloid metaplasia, is a chronic myeloproliferative disorder that is characterised by marrow fibrosis and extramedullary haematopoiesis. The origin of the disease remains an enigma and a source of confusion in management, not least because until recently no meaningful progress had been made regarding its pathophysiology. Research during the past decade in three interrelated areas may offer some hope for the future. First, it is now accepted that the fibroblast proliferation is a reactive, or secondary process and is not, as previously thought, a component of the underlying clonal haematopoiesis. Second, the nature and composition of both normal and myelofibrotic bone marrow stroma has largely been elucidated, and lastly, the pivotal role of inappropriate growth factor release from megakaryocytes as mediators of fibrogenesis has been recognised. This article aims to review the current understanding of the disease's pathogenesis, with particular emphasis on the part played by growth factors.
Clonality of haematopoiesis It was originally believed that bone marrow fibroblasts were derived from pluripotent haematopoietic stem cells and that the proliferative defect present in myelofibrosis also affected the fibroblasts. Jacobson et al,1
however, using G6PD isoenzyme analysis in a heterozygous female patient, showed for the first time that the fibroblasts were polyclonal, in contrast to the erythrocytes, platelets, and granulocytes. Subsequent studies, using cytogenetic analysis2 and fibroblast proliferation kinetics,3 have confirmed this observation. Recently, two independent strategies have added further support for haematopoetic clonality, namely probing for X-linked restriction fragment length polymorphisms by taking advantage of the non-random inactivation of the X chromosome,4 and N-ras gene mutation analysis.5 Interestingly, the latter study has provided evidence for a role for both T and B lymphocytes, a fact that could explain the observed immunological abnormalities.6 Further investigations are needed to determine if lymphocytic involvement is a consistent feature or whether lineage heterogeneity can occur as reported in other myeloproliferative disorders. 7 The concept of a clonal expansion of single multipotent stem cells has been strongly supported by the finding of increased numbers of multilineage (CFU-GEMM) and committed (CFU-GM, BFU-E, and CFU-MK) circulating progenitor cells.8 The molecular events that confer such a growth advantage remain unknown, although cytogenetic evidence points to abnormalities at specific chromosomal locations.9 One of the most common findings is deletion of 13q with consistent loss of 13ql4, the site of the retinoblastoma gene.'0 The pathogenetic importance, however, of the loss or inactivation of this tumour suppressor gene, as well as the reported N-ras oncogene mutations,5 11 requires further study on a larger number of patients. A proposed model of the disease's pathogenesis is outlined in fig 1. Composition of myelofibrotic stroma The constituents of normal and myelofibrotic extracellular matrices have a greater diversity and complexity than was apparent from routine histological examination. Immunological analysis, using specific antibodies, has shown a variety of collagen types, including, I, III, IV and V.'2 '3 Myelofibrotic stroma is characterised by an increase in total collagen, as measured by hydroxyproline content'4 with, in particular, deposition of the interstitial collagens type I and III.12 15 Type III collagen was assumed to form fibrous structures only after specific peptide extensions had been removed from the ends of the procollagen or "precursor" molecule. It is now apparent that a significant proportion of collagen type III still retains its amino-terminal peptide, even when assembled into fibrillar structures. In myelofibrotic stroma, therefore, procollagen type III deposition is also increased, especially in advanced disease, where it has a distribution similar to that of reticulin. ' increased plasma and urinary PDGF protein concentrations have also been reported in myeloproliferative diseases.'
Two independent groups3536 have documented high platelet PDGF concentrations in a small number of myelofibrotic patients. Katoh et al also reported increased mRNA expression, for both PDGF A and B chains, in megakaryocytes from myeloproliferative disorders. 37 It is therefore possible, at least in some cases, that increased PDGF synthesis may be pathogenetically important. Most studies, however, have found that myeloproliferative platelets contain reduced ax granule proteins and support the hypothesis of an abnormal leakage or release of PDGF in bone marrow, with consequent fibroblast proliferation.
The pathogenesis of myelofibrosis in acute megakaryoblastic leukaemia may be related to the release of PDGF from the blast cells. Several observations support this view; the c-sis gene, which encodes the chain of PDGF, may be expressed by megakaryoblastic leukaemia cells38 39; increased plasma PDGF concentrations have been reported in acute micromegakaryocytic leukaemia (fig 4),4 and breakpoints around the site of the PDGF-f gene, 22q13, are strongly associated with megakaryoblastic leukaemia in infants. 4' The release of PDGF, while undoubtedly inducing fibroblast growth, cannot account totally for the complexity of myelofibrotic stroma. PDGF does not, for example, have angiogenic properties, nor does it induce the transcription of genes coding for laminin, fibronectin, or the collagens. Additional growth factors must be involved, the most important of which is likely to be transforming growth factor-#. The reports of active TGF-f synthesis by megakaryoblasts48 and the finding of increased plasma concentrations in acute micromegakaryocytic leukaemia (fig 4) that correlated with increased bone marrow stromal turnover, 40 
